• Explore /
  • Poster
  • / Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC).

Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC).

Abstract Poster

Authors

Bjorn H. Gronberg

Bjorn H. Henning Gronberg

Norwegian University of Science and Technology (NTNU), Trondheim, Norway

Bjorn H. Henning Gronberg , Kristin Toftaker Killingberg , Øystein Fløtten , Maria Moksnes Bjaanæs , Tesfaye Madebo , Tine Schytte , Seppo Wang Langer , Signe Leonora Risumlund , Nina Helbekkmo , Kirill Neumann , Odd Terje Brustugun , Øyvind Yksnøy , Georgios Tsakonas , Jens Engleson , Sverre Fluge , Thor Naustdal , Liv Ellen Giske , Jan Nyman , Tarje Onsøien Halvorsen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02041845

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 8512)

DOI

10.1200/JCO.2023.41.16_suppl.8512

Abstract #

8512

Poster Bd #

139

Abstract Disclosures

Similar Posters

First Author: Evgenia Taranova

First Author: Armelle Vinceneux

First Author: Jane N. Winter

First Author: Pengbo Deng